Characteristic | Value |
---|---|
Patients (n = 88) | |
Male, n (%) | 57 (65) |
Female, n (%) | 31 (35) |
Mean age ± SD, years | 67.8 ± 0.84 |
Primary tumor | |
Colon, n (%) | 69 (78) |
Rectum, n (%) | 19 (22) |
Node status | |
Positive, n (%) | 65 (74) |
Negative, n (%) | 23 (26) |
Colorectal liver metastases (CLM) | |
Synchronous, n (%) | 22 (25) |
Metachronous, n (%) | 66 (75) |
Mean number ± SD | 2.7 ± 0.13 |
Number of 1–3 CLM, n (%) | 67 (76) |
Number of 4–5 CLM, n (%) | 21 (24) |
Mean maximum size ± SD, cm | 3.1 ± 0.1 |
Maximum size ≤ 3 cm, n (%) | 51 (65) |
Maximum size 3–5 cm, n (%) | 27 (35) |
CEA levels before RFA, ng/mL | |
Mean CEA level ± SD | 132.2 ± 16.3 |
CEA ≤ 100, n (%) | 51 (58) |
CEA > 100, n (%) | 37 (42) |
Main cause of unresectability | |
Expected liver remnant ≤ 30%, n (%) | 19 (22) |
Proximity to critical structures, n (%) | 22 (25) |
Medical comorbidity, n (%) | 37 (42) |
Patient refusal, n (%) | 10 (11) |
Systemic therapies before RFA | |
Mean number of lines ± SD | 1.5 ± 0.07 |
5-Fluorouracile, n (%) | 36 (41) |
5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), n (%) | 59 (67) |
5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), n (%) | 41 (47) |
+ Bevacizumab, n (%) | 13 (15) |
+ Cetuximab, n (%) | 5 (6) |
Systemic therapies before and after RFA | |
Mean number of lines ± SD | 3.1 ± 0.1 |
5-Fluorouracile, n (%) | 57 (65) |
5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), n (%) | 81 (92) |
5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), n (%) | 82 (93) |
+ Bevacizumab, n (%) | 40 (45) |
+ Cetuximab, n (%) | 16 (18) |
Response to the immediate systemic therapy before RFA | |
Partial remission, n (%) | 49 (56) |
Stable disease, n (%) | 13 (15) |
Progressive disease, n (%) | 26 (29) |
Recurrence after RFA | |
Median time to recurrence, months (range) | 8 (1–24) |
Local tumor progression (RFA-site), n (%) | 8 (9) |
Intrahepatic recurrence, n (%) | 33 (37) |
Extrahepatic recurrence, n (%) | 14 (16) |
Intra-/and extrahepatic recurrence, n (%) | 27 (31) |
No recurrence, n (%) | 6 (7) |